Home
About Us
Company News
Contact Us
Expanded Access Program
Home
About Us
Company News
Contact Us
Expanded Access Program
中文/EN
Company News
In the Press
Learn More
2021-10-29
Signet Therapeutics gets a $10M top-up for next-gen cancer bets
Learn More
News
Learn More
2025-04-01
Preclinical Data on SIGX1094, the First Targeted Therapy for Diffuse Gastric Cancer, to be Presented at AACR 2025
Learn More
2025-02-25
Expanded Access Policy
Learn More
2025-01-21
World’s First Potential Target Therapy for Diffuse Gastric Cancer Granted Fast Track Designation by the U.S. FDA
Learn More
